![Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210408005437/en/868792/5/Teva_Canada_-_AJOVY_Autoinjector.jpg)
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678529/5/Migraine+fact+2+of+3.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva launches pre-filled fremanezumab pen for anti-CGRP migraine therapy - Latest Pharmacy News | Business | Magazine - Pharmacy Business Teva launches pre-filled fremanezumab pen for anti-CGRP migraine therapy - Latest Pharmacy News | Business | Magazine - Pharmacy Business](https://www.pharmacy.biz/wp-content/uploads/sites/1/2019/10/Teva_Pharmaceuticals_logo.png)
Teva launches pre-filled fremanezumab pen for anti-CGRP migraine therapy - Latest Pharmacy News | Business | Magazine - Pharmacy Business
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678528/5/Migraine+fact+1+of+3.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva presents interim results from PEARL study on migraine treatment - European Pharmaceutical Manufacturer Teva presents interim results from PEARL study on migraine treatment - European Pharmaceutical Manufacturer](https://pharmaceuticalmanufacturer.media/downloads/8868/download/shutterstock_1658023018.jpg?cb=377128a851fb68d50c2b509deda5c595)